Opthea Ltd (OPT) presented new clinical data analysis from its completed Phase 1/2a trial of intravitreally injected OPT-302 with and without Lucentis (ranibizumab) for the treatment of wet AMD at the Retina Society 2018 Annual meeting. The initial Phase 1/2a trial results suggest that dual targeting of VEGF-C/D with OPT-302 and VEGF-A with standard of care agents is a promising strategy to treat wet AMD and other retinal vascular diseases.
http://crweworld.com/article/news-p...md-at-the-retina-society-2018-annual-meeting-
Opthea Ltd (OPT) presented new clinical data analysis from its...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
63.0¢ |
Change
-0.010(1.56%) |
Mkt cap ! $775.5M | |||
| Open | High | Low | Value | Volume |
| 64.0¢ | 64.5¢ | 62.8¢ | $1.826M | 2.864M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3870 | 63.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 64.0¢ | 259093 | 5 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| OPT (ASX) Chart |